23083093|t|N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an alpha7 nicotinic acetylcholine receptor agonist preclinical candidate.
23083093|a|alpha7 Nicotinic acetylcholine receptors (alpha7 nAChR) represent promising therapeutic candidates for the treatment of cognitive impairment associated with Alzheimer's disease (AD) and schizophrenia. A medicinal chemistry effort around previously reported compound 1 (SEN15924, WAY-361789) led to the identification of 12 (SEN78702, WYE-308775) a potent and selective full agonist of the alpha7 nAChR that demonstrated improved plasma stability, brain levels, and efficacy in behavioral cognition models.
23083093	0	71	N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide	Chemical	MESH:C577963
23083093	73	81	SEN78702	Chemical	MESH:C577963
23083093	83	93	WYE-308775	Chemical	MESH:C577963
23083093	135	174	alpha7 nicotinic acetylcholine receptor	Gene	1139
23083093	326	346	cognitive impairment	Disease	MESH:D003072
23083093	363	382	Alzheimer's disease	Disease	MESH:D000544
23083093	384	386	AD	Disease	MESH:D000544
23083093	392	405	schizophrenia	Disease	MESH:D012559
23083093	475	483	SEN15924	Chemical	MESH:C574768
23083093	485	495	WAY-361789	Chemical	MESH:C574768
23083093	530	538	SEN78702	Chemical	MESH:C577963
23083093	540	550	WYE-308775	Chemical	MESH:C577963

